Launch fueled by syndicate of blue-chip investors co-led by Qiming Venture Partners USA and venBio PartnersCompany’s proprietary end-to-end Encompass™ platform designs enhancement-targeting chimeric (ENTAC™) moleculesFounding team comprised of world-class scientific leadersWATERTOWN, Mass. (BUSINESS WIRE) Entact B.
4BIO Capital Portfolio Company Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
908 Devices Inc. (NASDAQ:NASDAQ:MASS) Q2 2022 Earnings Conference Call August 09, 2022 08:30 AM ET Company Participants Kelly Gura - Investor Relations Kevin Knopp - Chief Executive Officer.